MA49459A - Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1 - Google Patents
Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1Info
- Publication number
- MA49459A MA49459A MA049459A MA49459A MA49459A MA 49459 A MA49459 A MA 49459A MA 049459 A MA049459 A MA 049459A MA 49459 A MA49459 A MA 49459A MA 49459 A MA49459 A MA 49459A
- Authority
- MA
- Morocco
- Prior art keywords
- fusion protein
- receptor
- gipr
- glp
- improvement
- Prior art date
Links
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 title 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000002496 gastric effect Effects 0.000 title 1
- 230000006872 improvement Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000014187 peptide receptors Human genes 0.000 title 1
- 108010011903 peptide receptors Proteins 0.000 title 1
- 229940076376 protein agonist Drugs 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523216P | 2017-06-21 | 2017-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49459A true MA49459A (fr) | 2020-04-29 |
Family
ID=62904597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049459A MA49459A (fr) | 2017-06-21 | 2018-06-20 | Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200384119A1 (fr) |
| EP (2) | EP4353250A3 (fr) |
| JP (1) | JP7250706B2 (fr) |
| AU (2) | AU2018288852A1 (fr) |
| CA (1) | CA3066251A1 (fr) |
| MA (1) | MA49459A (fr) |
| MX (2) | MX2019015544A (fr) |
| WO (1) | WO2018237095A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3009650A1 (fr) | 2015-12-23 | 2017-06-29 | Amgen Inc. | Procede de traitement ou d'amelioration de troubles metaboliques a l'aide de proteines de liaison au recepteur du peptide inhibiteur gastrique (gipr) en association avec des agoni stes du glp-1 |
| CN117126279A (zh) | 2018-03-20 | 2023-11-28 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN112521501A (zh) * | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN114685643A (zh) * | 2020-12-29 | 2022-07-01 | 苏州康宁杰瑞生物科技有限公司 | 一种人glp-1多肽变体及其应用 |
| CN114685644A (zh) * | 2020-12-29 | 2022-07-01 | 苏州康宁杰瑞生物科技有限公司 | 一种人glp-1多肽变体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988001649A1 (fr) | 1986-09-02 | 1988-03-10 | Genex Corporation | Molecules de liaison de chaines de polypeptide simples |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| CA3009650A1 (fr) * | 2015-12-23 | 2017-06-29 | Amgen Inc. | Procede de traitement ou d'amelioration de troubles metaboliques a l'aide de proteines de liaison au recepteur du peptide inhibiteur gastrique (gipr) en association avec des agoni stes du glp-1 |
| JOP20190177A1 (ar) * | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
-
2018
- 2018-06-20 EP EP24158632.0A patent/EP4353250A3/fr active Pending
- 2018-06-20 US US16/623,756 patent/US20200384119A1/en active Pending
- 2018-06-20 JP JP2019566897A patent/JP7250706B2/ja active Active
- 2018-06-20 WO PCT/US2018/038634 patent/WO2018237095A1/fr unknown
- 2018-06-20 CA CA3066251A patent/CA3066251A1/fr active Pending
- 2018-06-20 EP EP18740407.4A patent/EP3642238A1/fr active Pending
- 2018-06-20 MA MA049459A patent/MA49459A/fr unknown
- 2018-06-20 MX MX2019015544A patent/MX2019015544A/es unknown
- 2018-06-20 AU AU2018288852A patent/AU2018288852A1/en active Pending
-
2019
- 2019-12-18 MX MX2023012010A patent/MX2023012010A/es unknown
-
2023
- 2023-12-11 AU AU2023282182A patent/AU2023282182A1/en active Pending
-
2024
- 2024-03-22 US US18/614,508 patent/US20240261421A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240261421A1 (en) | 2024-08-08 |
| MX2023012010A (es) | 2023-11-24 |
| US20200384119A1 (en) | 2020-12-10 |
| EP3642238A1 (fr) | 2020-04-29 |
| EP4353250A2 (fr) | 2024-04-17 |
| JP7250706B2 (ja) | 2023-04-03 |
| AU2023282182A1 (en) | 2024-01-04 |
| WO2018237095A1 (fr) | 2018-12-27 |
| CA3066251A1 (fr) | 2018-12-27 |
| AU2018288852A1 (en) | 2020-01-02 |
| EP4353250A3 (fr) | 2024-06-19 |
| MX2019015544A (es) | 2020-07-28 |
| JP2020524661A (ja) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49459A (fr) | Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1 | |
| MA47314A (fr) | Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur du glp-1 conjugués à des antagonistes du récepteur du peptide inhibiteur gastrique (gipr) | |
| MA44154A (fr) | Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1 | |
| MA49460A (fr) | Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1 | |
| MA53661A (fr) | Agonistes du récepteur farnésoïde x pour le traitement d'une maladie | |
| MX2017007136A (es) | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. | |
| MA55632A (fr) | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques | |
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| MA52570A (fr) | Formulations contenant des protéines de fusion du récepteur vegf à haute concentration | |
| HUE065080T2 (hu) | Glükagon-szerû peptid 1 receptor agonisták | |
| MA43168A (fr) | Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques | |
| MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
| MA56387A (fr) | Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf | |
| MA32031B1 (fr) | Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf | |
| MA49256A (fr) | Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose | |
| MA43828B1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| MA53234A (fr) | Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques | |
| MA56226A (fr) | Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale | |
| MA53711A (fr) | Antagonistes de récepteur alpha 2-adrénergiques de sous-type c (alpha-2c) pour le traitement de l'apnée du sommeil | |
| MA51136A (fr) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc | |
| BR112017024852A2 (pt) | antagonistas de receptor nk-1/nk-3 duplo para o tratamento de doenças dependentes de hormônio sexual | |
| IL291665A (en) | Inhibitors of receptor interaction with protein kinase i for the treatment of disease | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| MA56114A (fr) | Composés pour le traitement de troubles dépendant de la kinase |